Developmental and pediatric pharmacogenomics.
Children, as well as adults, should benefit from the discoveries of the genomic era. Many diseases with complex etiologies originate during childhood (e.g., asthma, autism, attention deficit/hyperactivity disorder, epilepsy and juvenile rheumatoid arthritis) and persist into adulthood. Attempts to better understand the genetic basis of age-specific disease processes requires an appreciation that the period of human development encompasses the prenatal period through adolescence, and is a rapidly changing, dynamic process. As a result, pharmacologic modulation of developing gene networks may have unintended and unanticipated consequences that do not become apparent or relevant until later in life. Thus, there is considerable potential for large-scale pharmacogenomic technologies to impact the development and utilization of new therapeutic strategies in children.
Leeder
J Steven
JS
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children's Mercy Hospital and Clinics, Kansas City, MO, USA. sleeder@cmh.edu
D002648:Child; D016503:Drug Delivery Systems; D015195:Drug Design; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D010372:Pediatrics / Q000639:trends*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods / Q000639:trends*; D011247:Pregnancy; D013678:Technology, Pharmaceutical
D004364:Pharmaceutical Preparations